CR20140489A - Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t - Google Patents

Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t

Info

Publication number
CR20140489A
CR20140489A CR20140489A CR20140489A CR20140489A CR 20140489 A CR20140489 A CR 20140489A CR 20140489 A CR20140489 A CR 20140489A CR 20140489 A CR20140489 A CR 20140489A CR 20140489 A CR20140489 A CR 20140489A
Authority
CR
Costa Rica
Prior art keywords
espirox
metilen
metil
onas
treatment
Prior art date
Application number
CR20140489A
Other languages
English (en)
Inventor
Norbert Schmees
Lars Röse
Tuula Valo
Katja Prelle
Reinhard Nubbemeyer
Henriikka Korolainen
Harri Jukarainen
Original Assignee
Bayer Pharma AG
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Shering Pharma Ag filed Critical Bayer Pharma AG
Publication of CR20140489A publication Critical patent/CR20140489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

Uso intrauterino de 18-metil-15fÀ,16fÀ-metilen-19-nor-20-espirox-4-en-3-onas de formula general (1)
CR20140489A 2012-04-23 2014-10-23 Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t CR20140489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012206653 2012-04-23
PCT/EP2013/058152 WO2013160200A1 (de) 2012-04-23 2013-04-19 ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN

Publications (1)

Publication Number Publication Date
CR20140489A true CR20140489A (es) 2014-12-24

Family

ID=48141995

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140489A CR20140489A (es) 2012-04-23 2014-10-23 Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t

Country Status (28)

Country Link
US (1) US20150119372A1 (es)
EP (1) EP2841073A1 (es)
JP (1) JP2015514789A (es)
KR (1) KR20150005548A (es)
CN (1) CN104379149A (es)
AR (1) AR090800A1 (es)
AU (1) AU2013251842A1 (es)
BR (1) BR112014026086A2 (es)
CA (1) CA2871001A1 (es)
CL (1) CL2014002857A1 (es)
CO (1) CO7111253A2 (es)
CR (1) CR20140489A (es)
CU (1) CU20140120A7 (es)
DO (1) DOP2014000240A (es)
EA (1) EA201491917A1 (es)
EC (1) ECSP14024263A (es)
GT (1) GT201400225A (es)
HK (1) HK1206271A1 (es)
IL (1) IL235096A0 (es)
MA (1) MA37443A1 (es)
MX (1) MX2014012848A (es)
PE (1) PE20142437A1 (es)
PH (1) PH12014502371A1 (es)
SG (1) SG11201406583QA (es)
TN (1) TN2014000445A1 (es)
TW (1) TW201345530A (es)
UY (1) UY34759A (es)
WO (1) WO2013160200A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TW201345530A (zh) 2013-11-16
MA37443A1 (fr) 2016-05-31
CU20140120A7 (es) 2015-02-26
DOP2014000240A (es) 2015-02-15
EP2841073A1 (de) 2015-03-04
WO2013160200A1 (de) 2013-10-31
CN104379149A (zh) 2015-02-25
EA201491917A1 (ru) 2015-04-30
CO7111253A2 (es) 2014-11-10
SG11201406583QA (en) 2014-11-27
CA2871001A1 (en) 2013-10-31
IL235096A0 (en) 2014-12-31
PE20142437A1 (es) 2015-01-31
PH12014502371A1 (en) 2015-01-12
KR20150005548A (ko) 2015-01-14
AU2013251842A1 (en) 2014-11-06
BR112014026086A2 (pt) 2017-07-18
ECSP14024263A (es) 2015-12-31
JP2015514789A (ja) 2015-05-21
TN2014000445A1 (en) 2016-03-30
AR090800A1 (es) 2014-12-10
CL2014002857A1 (es) 2015-02-06
MX2014012848A (es) 2015-02-05
GT201400225A (es) 2016-01-22
US20150119372A1 (en) 2015-04-30
HK1206271A1 (en) 2016-01-08
UY34759A (es) 2013-11-29

Similar Documents

Publication Publication Date Title
MX2015003140A (es) Formulaciones de enzalutamida.
CL2017003404A1 (es) Compuestos antibacterianos
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CR20150462A (es) Inhibidores de erk y sus usos
ECSP15026557A (es) Compuestos y sus métodos de empleo
DOP2015000274A (es) Compuestos químicos
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2015000942A1 (es) Compuestos de benceno sustituido.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
CO7350653A2 (es) Retinoides y uso de los mismos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX369290B (es) Inhibidores de fbx03.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina